Systemic therapies for intrahepatic cholangiocarcinoma

JOURNAL OF HEPATOLOGY

卷:72

Review

Kelley, Robin Kate¹  Bridgewater, John²  Gores, Gregory J.³  Zhu, Andrew X.⁴ 

[1] Univ Calif San Francisco, San Francisco, CA 94143 USA

[2] UCL Canc Inst, Dept Med Oncol, London, England

[3] Mayo Clin, Div Gastroenterol & Hepatol, Rochester, MN 55905 USA

[4] Harvard Med Sch, Canc Ctr, Massachusetts Gen Hosp, Boston, MA 02115 USA

关键词: Adjuvant therapy;    Checkpoint inhibitors;    FGFR;    IDH;   

DOI  :  10.1016/j.jhep.2019.10.009

来源: Elsevier

【 摘 要 】

Intrahepatic cholangiocarcinoma (iCCA) is a highly lethal hepatobiliary neoplasm whose incidence is increasing. Largely neglected for decades as a rare malignancy and frequently misdiagnosed as carcinoma of unknown primary, considerable clinical and investigative attention has recently been focused on iCCA worldwide. The established standard of care includes first-line (gemcitabine and cisplatin), second-line (FOLFOX) and adjuvant (capecitabine) systemic chemotherapy. Compared to hepatocellular carcinoma, iCCA is genetically distinct with several targetable genetic aberrations identified to date. Indeed, FGFR2 and NTRK fusions, and IDH1 and BRAF targetable mutations have been comprehensively characterised and clinical data is emerging on targeting these oncogenic drivers pharmacologically. Also, the role of immunotherapy has been examined and is an area of intense investigation. Herein, in a timely and topical manner, we will review these advances and highlight future directions of research. (C) 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.

【 授权许可】

Free